Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$0.79 - $1.59 $54,517 - $109,724
-69,009 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$1.36 - $2.94 $115,288 - $249,226
-84,771 Reduced 55.12%
69,009 $94,000
Q3 2021

Nov 15, 2021

BUY
$2.97 - $4.84 $456,726 - $744,295
153,780 New
153,780 $463,000
Q2 2021

Aug 16, 2021

SELL
$3.71 - $5.13 $60,873 - $84,173
-16,408 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$4.08 - $14.75 $66,944 - $242,018
16,408 New
16,408 $71,000
Q4 2020

Feb 16, 2021

SELL
$11.06 - $14.01 $1.03 Million - $1.31 Million
-93,493 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$10.26 - $14.55 $959,238 - $1.36 Million
93,493 New
93,493 $1.13 Million

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.